BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

Contributed by: GlobeNewswire

Tags

medtech

More Like This

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform

Alentis Strengthens Management Team with Key Appointments

Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer

PR Newswire associated0

Dr. Eyal S. Ron Joins AmacaThera Board of Directors to Drive Strategic Growth and Accelerate Innovation in Long-Acting Therapies